PT - JOURNAL ARTICLE AU - Rakibul M. Islam AU - Md. Nuruzzaman Khan AU - John C. Oldroyd AU - Juwel Rana AU - Enayet K. Chowdhury AU - Md Nazmul Karim AU - Mohammad Bellal Hossain TI - Prevalence of diabetes and prediabetes among Bangladeshi adults and associated factors: Evidence from the Demographic and Health Survey, 2017-18 AID - 10.1101/2021.01.26.21250519 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.26.21250519 4099 - http://medrxiv.org/content/early/2021/01/26/2021.01.26.21250519.short 4100 - http://medrxiv.org/content/early/2021/01/26/2021.01.26.21250519.full AB - Aim To estimate the age-standardized prevalence of diabetes and prediabetes, and to identify factors associated with these conditions at individual, household, and community levels.Methods Data from 11, 952 Bangladeshi adults aged 18+ available from the most recent nationally representative Bangladesh Demographic and Health Survey 2017-18 were used. Anthropometric measurements and fasting blood glucose samples were taken as part of the survey. Prevalence estimates of diabetes and prediabetes were age-standardised, and risk factors were identified using multilevel mix-effect Poisson regression models with robust variance.Results The overall age-standardized prevalence of diabetes was 12.8% (95%CI 11.2-14.3) (men: 12.8%, women: 12.7%), and prediabetes was 14.0% (95%CI 12.6-15.4) (men: 12.1%, women: 16.5%). Among people with diabetes, 61.5% were unaware that they had the condition, and only 35.2% were receiving treatment regularly. Factors associated with an increased risk of having diabetes were increasing age, male, overweight/obesity, hypertension, highest wealth quintile and living in Dhaka division. Individuals being underweight or currently working were less likely to develop diabetes.Conclusion Diabetes and prediabetes affect a substantial proportion (over one-quarter) of the Bangladeshi adult population. Continuing surveillance and effective prevention and control measures, with a particular focus on obesity reduction and hypertension management, are urgently needed.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementStudy analysed secondary data and there was no funding for the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The survey, including biomarker measurements, was approved by the institutional review board of ICF and the National Research Ethics Committee of the Bangladesh Medical Research Council. Informed consent was obtained from all participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available on request once the article is published